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Abstract
Background: The gene family KCNE1-5, which encode modulating b-subunits of several repolarising K
+-ion
channels, has been associated with genetic cardiac diseases such as long QT syndrome, atrial fibrillation and
Brugada syndrome. The minK peptide, encoded by KCNE1, is attached to the Z-disc of the sarcomere as well as the
T-tubules of the sarcolemma. It has been suggested that minK forms part of an “electro-mechanical feed-back”
which links cardiomyocyte stretching to changes in ion channel function. We examined whether mutations in
KCNE genes were associated with hypertrophic cardiomyopathy (HCM), a genetic disease associated with an
improper hypertrophic response.
Results: The coding regions of KCNE1, KCNE2, KCNE3, KCNE4, and KCNE5 were examined, by direct DNA
sequencing, in a cohort of 93 unrelated HCM probands and 188 blood donor controls.
Fifteen genetic variants, four previously unknown, were identified in the HCM probands. Eight variants were non-
synonymous and one was located in the 3’UTR-region of KCNE4. No disease-causing mutations were found and no
significant difference in the frequency of genetic variants was found between HCM probands and controls. Two
variants of likely functional significance were found in controls only.
Conclusions: Mutations in KCNE genes are not a common cause of HCM and polymorphisms in these genes do
not seem to be associated with a propensity to develop arrhythmia
Background
Hypertrophic cardiomyopathy (HCM) is a condition
characterised by increased wall (predominantly septal)
thickness, diastolic dysfunction, and an increased risk of
heart failure, stroke and cardiac arrhythmia [1]. The dis-
ease has a prevalence of 1:500 in young adults [2], and
is considered a hereditary disease caused by mutations
in more than 12 genes [3], most of which encode pro-
teins of the sarcomere. The disease exhibits considerable
intra-allelic as well as phenotypic heterogeneity. Pre-
sently, a genetic aetiology can be identified in 70% of
familial cases and 30% of non-familial cases [3].
Recently, mutations in genes coding for ion channels
have been shown to cause cardiomyopathy. Mutations
in SCN5A, coding for the a-subunit of the ion channel
conducting the depolarising INa -current [4,5], and in
ABCC9 [6], coding for the cardiac specific SUR2A subu-
nit of the KATP potassium channel, have been associated
with dilated cardiomyopathy (DCM). The DCM caused
by mutations in both SCN5A and ABCC9 is accompa-
nied by cardiac arrhythmia.
The KCNE-gene family (KCNE1-5) encodes five small
single transmembrane peptides (minK and MiRP1-4,
respectively) that function as b-subunits to potassium
and pacemaker ion channels [7,8]. The KCNE peptides
confer distinctive characteristics to a variety of currents
[9-11]. For example, the slow increase and high conduc-
tance characteristic of IKsis conferred by minK (encoded
by KCNE1)t ot h ea-subunit (encoded by KCNQ1)[ 1 2 ] .
The KCNE peptides are also involved in correct traffick-
ing of a-subunits [13]. Mutations in KCNE genes have
been associated with a number of diseases, i.e. cardiac
arrhythmia by mutations in KCNE1 (long QT syndrome
and Jervell Lange Nielsen Syndrome) [14-17], KCNE2
(long QT syndrome, atrial fibrillation, drug induced ven-
tricular fibrillation) [18-20], KCNE3 (Brugada syndrome)
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KCNE3 have also been associated with periodic paralysis
and hypo-and hyperkalemic disorders [23]. Furthermore,
kcne2 null mice develop rhythm disturbances [24] and
kcne2 null pups to kcne2 null dams develop hypertrophy
among other abnormalities as a consequence of
hypothyroidism [25]. This suggests that in addition to
the development of arrhythmias, mutations in KCNE2
could give rise to cardiac hypertrophy through the dys-
regulation of thyroid hormones. Likewise, other investi-
gations using kcne2 null mice have revealed an
association with gastric pathology [26]. These finding
suggest that the KCNE genes may influence phenotypic
presentation of HCM in multiple ways.
All KCNE genes are expressed in the heart but to a
varying extent [27]. The minK and MirP peptides exhi-
bit considerable functional promiscuity, consequently,
they may substitute for each other with different a-sub-
units [28] and the relative levels of peptides in different
parts of the heart influence the regional variation of ion
channel function [27].
Yeast-two-hybrid (Y2H) experiments have shown that
minK is linked to the z-disc of the sarcomere via inter-
action with titin-cap (telethonin) [29]. The link between
the T-tubule, where minK is attached and the Z-disc,
has been suggested to constitute a “mechano-electrical
feed-back system”, linking the function of repolarising
ion channels to stretch of the cardiomyocytes [29].
The Z-disc proteins are involved in the control of car-
diac hypertrophy as mutations in the protein constitu-
ents of the Z-disc, T-cap, titin, muscle LIM protein,
actinin and cypher/ZASP, have been shown to cause
both HCM and DCM [30,31]. The electrical remodelling
seen in heart failure is characterised by a marked
increase in the expression of KCNE1 [32] in the heart.
We hypothesised that variants in KCNE genes, might
result in changes in mechano-electrical feed-back, and
could be responsible for a maladaptation of the stretch-
response of the heart. This could explain an exaggerated
hypertrophic response and thus HCM development in
patients with mutations in Z-disc proteins. Alternatively,
an increased occurrence of electrophysiologically signifi-
cant KCNE variants might explain the increased propen-
sity of arrhythmia in HCM.
We screened the genes KCNE1, KCNE2, KCNE3,
KCNE4,a n dKCNE5 for genetic variants in 93 unrelated
probands with HCM and related the findings to occur-
rence of disease or propensity to a particular phenotype.
Results
No putative disease causing mutations were found in
HCM index patients in any of the five KCNE genes. Fif-
teen genetic variants were identified; four of which were
previously unknown. Fourteen of the genetic variants
were located in the coding regions of the genes. The
variants are detailed in Table 1. All variants were in
Hardy-Weinberg equilibrium, when the variants were so
frequent that this could be assessed.
Two variants, p.M1T in KCNE3 and p.E141A in
KCNE4, were found in single controls. The p.M1T var-
iant abolishes the translation initiation codon and most
likely results in haplo-insufficiency. The p.E141A var-
iant, affects an amino acid which is conserved in seven
species, and represents a charge change and may well
modify the functional properties.
Some of the identified variants have previously been
associated with arrhythmia, i.e. p.S38G in KCNE1 and p.
P33S in KCNE5, that are known polymorphisms asso-
ciated with increased risk of atrial fibrillation. There was
no significant difference in the frequency of any of the
polymorphisms between HCM and the normal popula-
t i o n .T w ov a r i a n t s ,i . e .p . D 8 5 Ni nKCNE1 and p.T8A in
KCNE2 have previously been associated with increased
risk for drug-induced ventricular fibrillation. For both
variants, the frequency was lower in HCM, for p.D85N
rare allele frequency 0.5% vs 1.2% in controls, and for p.
T8A a rare allele frequency of 0.5% vs. 4.3% in controls.
For both variants the allele frequency was so low, how-
ever, that the difference is not significant when compen-
sating for multiple comparisons.
The p.R83H variant in KCNE3 has previously been
associated with hypo- and hyper-kalemia and paralysis
[7], and here it was found in two cases. In one family the
mutation was co-inherited with a mutation in troponin T
and in another the comprehensive sarcomeric gene
screening had not revealed other mutations. There were
no special clinical characteristics of the carriers of the p.
R83H variant. However, the p.R83H has, following the
association with hypo- and hyper-kalemic paralysis, been
described as a polymorphism in several populations [33].
None of the identified variants had any significant
effect on splicing, i.e. did not interfere in silico with
ESEs or SSEs.
Discussion
The KCNE genes do not, despite the association with
electromechanical feedback, seem to cause HCM, even
though the number of probands examined does not pre-
clude an involvement at the level of less than 1%. How-
ever, except in special cases, there does not seem to be
any reason for including KCNE gene screening in the
screening of genes in the genetic work-up of HCM.
The frequency of arrhythmia associated genetic var-
iants was so low that it did not convincingly differ from
that of controls and it cannot explain the increased
occurrence of arrhythmia in HCM [34]. However, the
previously arrhythmia-associated variants p.D85N
[18,35,36] and p.T8A [7] both occurred more frequently
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however, that a small minority of HCM patients with
arrhythmia associated variants in KCNE genes have an
increased propensity for arrhythmia.
The finding of very rare genetic variants with likely
functional significance, i.e. p.M1T in KCNE3 and p.
E141A in KCNE4, in controls is interesting and suggests
that such variants may contribute to the arrhythmia risk
in various conditions in the general population.
Conclusions
Our findings suggest that neither KCNE1,d e s p i t ei t s
physical association with the Z-disc [29], nor the other
KCNE genes are common causes of HCM.
Methods
Patients
Ninety-three unrelated consecutively diagnosed HCM
patients identified at, or referred to, Copenhagen Univer-
sity Hospital, Rigshospitalet, Copenhagen, Denmark were
included in the study. All patients were of Northern Eur-
opean descent. Patients were subjected to a full clinical
evaluation including family history, physical examination,
echocardiography and ECG. All fulfilled classical diag-
nostic criteria for HCM [37,38]. The mean age of index
patients was 49 years, 62% were male, and 48% were
familial. Ninety-two % had septal hypertrophy, 6% apical
hypertrophy and 2% mid-ventricular hypertrophy. All
patients had been screened for mutations in the coding
regions of MYH7, MYBPC3, TTNT2, TPM1, TNNI3,
MYL3, MYL2, ACTC, TCAP, CSRP3, and exons 3,7,14,18,
and 49 of TTN, as detailed in a previous study [3]. All
index patients were also screened for mutations in GLA.
In 32 index patients this screening had identified pre-
sumably disease-causing mutations, i.e. 12 in MYH7,8i n
MYBPC3, 2 in each of TNNT2, TNNI3 and GLA,1i n
each of ACTC, TPM1, MYL3 and MYL2. Two patients
were carriers of mutations in both MYL2 and MYH7.A
control panel of 188 (50% men) anonymous blood donors
obtained from Rigshospitalet, Copenhagen, were used.
Molecular genetic studies
Genomic DNA was isolated from whole blood samples
(Qiagen, Hilden, Germany). The genomic sequences of
KCNE1, KCNE2, KCNE3, KCNE4,a n dKCNE5 were
used for designing intronic primers covering the coding
region of the genes. Primers and conditions are given in
Table 2. DNA sequencing was performed using Big Dye
technology. Variant numbering was verified using the
Mutalyzer program [39].
Disease-causation and association
Genetic variants were considered disease-causing if 1)
t h en u c l e o t i d ev a r i a t i o nw a sd e d u c e dt or e s u l ti na
Table 1 Genetic variants within the KCNE genes identified in a Danish HCM cohort
nucleotide peptide rs# Pop rare allele frequency HCM rare allele frequency Disease association Reference
KCNE1: [NM_000219.2/NP_000210.2]
c.24 G > A p.A8A 0.000 0.005
c.112G > A p.G38S rs17846179 0.494 0.376 AF [40]
c.253G > A p.D85N rs1805128 0.012 0.005 IVF, drug induced [18,35,36]
KCNE2: [NM_172201.1/NP_751951.1]
c.22A > G p.T8A rs2234916 0.043 0.005 IVF, drug-induced
KCNE3: [NM_005472.4/NP_005463.1]
c.2T > C p.M1T 0.003 0.000
c.198T > C p.F66F rs2270676 0.104 0.080
c.248G > A p.R83H rs17215437 0.003 0.011 Hypokalemia [7,41]
KCNE4: [NM_080671.2/NP_542402.2]
c.69C > T p.S23S rs12720447 0.011 0.006
c.81C > T p.G27G rs3795886 0.730 0.717
c.264T > C p.P88P rs10201907 0.949 0.933
c.422A > C p.E141A 0.003 0.000
c.435T > G p.D145E rs12621643 0.712 0.724
c.471G > A p.E157E 0.042 0.023
c.*19G > C 3’UTR rs10189762 0.059 0.046
KCNE5: [NM_012282.2/NP_036414.1]
c.97C > T p.P33S rs17003955 0.206* 0.150* AF [22,42]
* gender corrected value
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2) if relevant, the variation affected a conserved amino
acid; 3) the variation co-segregated with the disease in
affected family members and; 4) if the variation was not
identified among 188 ethnically controlled samples. In
the absence of available family members for co-segrega-
tion studies, disease association was presumed if criteria
1, 2 and 4 were fulfilled. If the mutation had previously,
in accordance with the criteria mentioned here and/or
relevant functional studies, been associated with disease,
disease causation was presumed when just the criteria 1
and 4 were met. The association between gene variants
and disease was assessed by comparing the distribution
of variants in disease group and controls. c
2-testing was
used to examine for significant association using a level
of significance of 0.05, with correction for multiple com-
parisons, if such were made.
Bioinformatics
ESE/SSE-in silico assessment was performed using the
online web-servers: FAS-ESS [34], RESCUE-ESE [35],
HMMgene [36], GENSCANW [37] and ESEFinder v.3.0
[38]. Multiple species alignments were performed using
ClustalW2 [39].
Ethics
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